【摘要】：目的觀察鹽酸吡格列酮膠囊聯(lián)合纈沙坦膠囊治療代謝綜合征的臨床療效及安全性。方法將48例代謝綜合征患者隨機分為對照組24例和試驗組24例。對照組予以二甲雙胍1.0 g,qd,口服+纈沙坦80 mg,qd,口服;試驗組予以鹽酸吡格列酮15 mg,qd,口服+纈沙坦80 mg,qd,口服。2組患者均治療3個月。比較2組患者的臨床療效、收縮壓(SBP)、舒張壓(DBP)、血清中三酰甘油(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)、空腹血糖(FPG)、空腹胰島素(FINS)、胰島素抵抗指數(shù)(HOMA-IR),以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗組和對照組的總有效率分別為91.67%(22/24例)和79.17%(19/24例),差異有統(tǒng)計學(xué)意義(P0.05)。治療后,試驗組和對照組的SBP分別為(140.74±7.37)和(146.34±7.46)mm Hg,DBP分別為(89.58±4.36)和(96.37±4.86)mm Hg,TG分別為(1.65±0.23)和(2.05±0.29)mmol·L~(-1),LDL-C分別為(2.43±0.31)和(2.97±0.35)mmol·L~(-1),HDL-C分別為(1.74±0.22)和(1.31±0.11)mmol·L~(-1),FPG分別為(5.27±0.75)和(6.48±0.86)mmol·L~(-1),FINS分別為(6.73±0.89)和(8.05±1.12)pmol·L~(-1),HOMA-IR分別為(3.63±0.37)和(4.15±0.32),差異均有統(tǒng)計學(xué)意義(均P0.05)。試驗組的藥物不良反應(yīng)主要有輕度顏面水腫、頭痛,對照組的藥物不良反應(yīng)主要有消化道反應(yīng)、頭暈。試驗組和對照組的藥物不良反應(yīng)發(fā)生率分別為8.33%和12.50%,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論鹽酸吡格列酮膠囊聯(lián)合纈沙坦膠囊治療代謝綜合征的臨床療效確切,其能顯著降低患者的血脂、血糖、血壓水平,減輕胰島素抵抗,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of pioglitazone hydrochloride capsule combined with valsartan capsule in the treatment of metabolic syndrome. Methods 48 patients with metabolic syndrome were randomly divided into control group (n = 24) and test group (n = 24). The control group was given metformin 1.0g, QD, oral valsartan 80 mg,qd, and pioglitazone hydrochloride 15 mg,qd, oral valsartan 80 mg,qd,. Both groups were treated with valsartan 80 mg,qd, for 3 months. The clinical effects of systolic blood pressure (SBP), diastolic blood pressure (DBP), triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and fasting blood glucose (FPG), were compared between the two groups. Fasting insulin (FINS), insulin resistance index (HOMA-IR) and adverse drug reactions. Results after treatment, the total effective rate of treatment group and control group were 91.67% (22 / 24) and 79.17% (19 / 24) respectively, the difference was statistically significant (P0.05). After treatment, the SBP of test group and control group were (140.74 鹵7.37) and (146.34 鹵7.46) mm Hg,DBP, (89.58 鹵4.36) and (96.37 鹵4.86) mm Hg,), respectively. TG was (1.65 鹵0.23) and (2.05 鹵0.29) mmol 路L ~ (- 1), LDL-C was (2.43 鹵0.31) and (2.97 鹵0.35) mmol 路L ~ (- 1), respectively. HDL-C were (1.74 鹵0.22) and (1.31 鹵0.11) mmol 路L ~ (- 1), FPG were (5.27 鹵0.75) and (6.48 鹵0.86) mmol 路L ~ (- 1), respectively. FINS was (6.73 鹵0.89) and (8.05 鹵1.12) pmol 路L ~ (- 1), HOMA-IR was (3.63 鹵0.37) and (4.15 鹵0.32), respectively (P 0.05). The adverse drug reactions in the experimental group were mild facial edema and headache, while those in the control group were mainly alimentary tract reactions and dizziness. The incidence of adverse drug reactions in test group and control group was 8.33% and 12.50%, respectively, and there was no significant difference between the two groups (P0.05). Conclusion pioglitazone hydrochloride capsule combined with valsartan capsule is effective in the treatment of metabolic syndrome. It can significantly reduce the level of blood lipid, blood glucose and blood pressure, reduce insulin resistance, and does not increase the incidence of adverse drug reactions.
【作者單位】： 南華大學(xué)附屬第二醫(yī)院心血管內(nèi)科;
【基金】：國家醫(yī)學(xué)教育發(fā)展中心醫(yī)學(xué)研究課題基金資助項目(2010-24-03-009)
【分類號】：R589

【相似文獻】

相關(guān)期刊論文 前10條

1 龐嫵燕;劉揚;趙春燕;;鹽酸吡格列酮單藥治療初發(fā)老年2型糖尿病[J];中原醫(yī)刊;2006年10期

2 駱建華;;鹽酸吡格列酮治療30例2型糖尿病的療效觀察[J];中國醫(yī)藥導(dǎo)報;2007年35期

3 王波;;鹽酸吡格列酮治療136例初發(fā)2型糖尿病患者的臨床觀察[J];中國醫(yī)藥導(dǎo)報;2009年08期

4 武曉泓,周紅文,張梅,劉超,狄福松,何戎華;鹽酸吡格列酮對2型糖尿病患者血可溶性血管細胞黏附分子-1的影響[J];南京醫(yī)科大學(xué)學(xué)報(自然科學(xué)版);2002年05期

5 楊小潔,溫晨東;鹽酸吡格列酮治療2型糖尿病臨床研究[J];臨床醫(yī)藥實踐;2003年02期

6 富琳巖,王麗敏,范希超;鹽酸吡格列酮與苯那普利聯(lián)合應(yīng)用對2型糖尿病合并高血壓的影響[J];中國慢性病預(yù)防與控制;2003年01期

7 梁杏歡;林健;羅佐杰;沈寒蕾;張R，

本文編號：2453779